TransMedics Group, Inc.

TransMedics Group, Inc.

TMDX·NASDAQ

$69.69

+3.2%
HealthcareMedical - Devices

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

At a Glance

Live Snapshot
Market Cap$2.41B
EPS5.6000
P/E Ratio12.44
Earnings Date07/29/2026

tmdx

Total Debt

Last Annual Value

469.69M

3-Year CAGR

91%

5-Year CAGR

68%

10-Year CAGR

50%

TransMedics Group, Inc.

TransMedics Group, Inc. Competitors Analysis of Total Debt

TMDX · NASDAQ
CompanyTotal Debt
CAGR 3Y
CAGR 5Y
CAGR 10Y
469.69M
-3.1%60.7%49.5% 
36.46M
11.5%88.9%N/A
139.64M
-28.6%-18.3%N/A
2.04B
14.0%7.9%17.4%
8.04M
-20.1%N/AN/A
82.25M
-1.0%35.6%N/A
351.00M
7.4%4.2%-4.1%
202.00K
49.9%1.6%N/A
430.10M
12.9%N/AN/A
0.00
N/AN/AN/A
IMVT logo
Immunovant, Inc.
NASDAQ:IMVT
72.00K
-61.1%-53.8%N/A
TransMedics Group, Inc.

TransMedics Group, Inc. Fair Value Envelope

TMDX · NASDAQ

Our analysis suggests that TMDX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $69.69, this represents a potential HIDDEN relative to our calculated worth for TransMedics Group, Inc..

Intrinsic Value
Current Price: $69.69